What is Pharma-Bio Serv Inc's earnings per share (EPS)?

Pharma-Bio Serv Inc (PBSV) reported diluted earnings per share of $-0.00 for fiscal year 2025. This represents a 88.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Pharma-Bio Serv Inc Financials

PBSV

Source SEC Filings (10-K/10-Q) Data as of Apr 30, 2026 Currency USD FYE October

This page shows Pharma-Bio Serv Inc (PBSV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PBSV FY2025 2026-06-15

Legacy cash reserves, not current earnings, have been financing dividends and a shrinking asset base as revenue stays subdued.

Across FY2021-FY2025, the company produced only $2.5M of operating cash flow while paying roughly $10.3M in dividends. That gap explains why cash fell to $5.8M by FY2025 despite liabilities of just $3.3M: the business still has balance-sheet room, but its distribution policy has been consuming the cushion faster than operations replenish it.

FY2025 shows margin repair without volume recovery: revenue was only $9.0M, yet gross margin reached 32.3% and the operating loss narrowed materially. That pattern points to better cost absorption or leaner execution on a smaller sales footprint, not a return to the earlier revenue base.

Since FY2023, assets have been shrinking faster than obligations, with total assets moving from $19.2M to $13.5M while liabilities also eased. With a 4.0x current ratio and no disclosed long-term debt, the immediate issue looks more like buffer erosion than lender pressure, but repeated cash outflows still narrow the company’s room to self-fund.

Financial Health Signals

Financial health score pending refresh

We are recalculating Pharma-Bio Serv Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Safe

4.05

Pharma-Bio Serv Inc scores 4.05, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Pharma-Bio Serv Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

2.14x

For every $1 of reported earnings, Pharma-Bio Serv Inc generates $2.14 in operating cash flow (-$215K OCF vs -$100K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$9.0M

YoY-5.3%

5Y CAGR-16.0%

10Y CAGR-9.1%

Pharma-Bio Serv Inc generated $9.0M in revenue in fiscal year 2025. This represents a decrease of 5.3% from the prior year.

EBITDA

-$578K

YoY+54.3%

Pharma-Bio Serv Inc's EBITDA was -$578K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 54.3% from the prior year.

Net Income

-$100K

YoY+87.1%

Pharma-Bio Serv Inc reported -$100K in net income in fiscal year 2025. This represents an increase of 87.1% from the prior year.

EPS (Diluted)

$-0.00

YoY+88.2%

Pharma-Bio Serv Inc earned $-0.00 per diluted share (EPS) in fiscal year 2025. This represents an increase of 88.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$222K

YoY+69.5%

Pharma-Bio Serv Inc generated -$222K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 69.5% from the prior year.

Cash & Debt

$5.8M

YoY-21.1%

5Y CAGR-21.2%

10Y CAGR-8.8%

Pharma-Bio Serv Inc held $5.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

23M

YoY-0.2%

5Y CAGR-0.1%

10Y CAGR-0.1%

Pharma-Bio Serv Inc had 23M shares outstanding in fiscal year 2025. This represents a decrease of 0.2% from the prior year.

Margins & Returns

Gross Margin

32.3%

YoY+5.9pp

5Y CAGR+1.4pp

10Y CAGR+0.3pp

Pharma-Bio Serv Inc's gross margin was 32.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 5.9 percentage points from the prior year.

Operating Margin

-7.1%

YoY+6.5pp

5Y CAGR-17.4pp

10Y CAGR-14.7pp

Pharma-Bio Serv Inc's operating margin was -7.1% in fiscal year 2025, reflecting core business profitability. This is up 6.5 percentage points from the prior year.

Net Margin

-1.1%

YoY+7.1pp

5Y CAGR-10.6pp

10Y CAGR-8.1pp

Pharma-Bio Serv Inc's net profit margin was -1.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 7.1 percentage points from the prior year.

Return on Equity

-1.0%

YoY+5.5pp

5Y CAGR-10.6pp

10Y CAGR-8.3pp

Pharma-Bio Serv Inc's ROE was -1.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 5.5 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

$31K

YoY+179.2%

5Y CAGR+79.3%

10Y CAGR-15.5%

Pharma-Bio Serv Inc spent $31K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 179.2% from the prior year.

Capital Expenditures

$7K

YoY-95.8%

5Y CAGR-34.6%

10Y CAGR-32.6%

Pharma-Bio Serv Inc invested $7K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 95.8% from the prior year.

PBSV Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$9.0M-5.3%	$9.5M-44.0%	$17.0M-12.5%	$19.4M-3.6%	$20.1M-6.7%	$21.6M
Cost of Revenue	$6.1M-12.9%	$7.0M-41.3%	$11.9M-18.0%	$14.5M-1.6%	$14.8M-1.0%	$14.9M
Gross Profit	$2.9M+15.7%	$2.5M-50.3%	$5.1M+3.8%	$4.9M-8.9%	$5.4M-19.6%	$6.7M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$3.5M-6.7%	$3.8M-3.7%	$3.9M+6.5%	$3.7M-59.8%	$9.2M+107.5%	$4.4M
Operating Income	-$638K+50.5%	-$1.3M-215.2%	$1.1M-4.9%	$1.2M+130.5%	-$3.9M-273.2%	$2.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$6K-72.0%	$22K-94.1%	$377K+107.7%	$182K-14.8%	$213K-10.8%	$239K
Net Income	-$100K+87.1%	-$778K-159.4%	$1.3M+30.1%	$1.0M+148.2%	-$2.1M-201.9%	$2.1M
EPS (Diluted)	$-0.00+88.2%	$-0.03-159.6%	$0.06	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$2.7M+17.8%	$2.3M+6.8%	$2.1M+9.5%	$2.0M-18.8%	$2.4M-2.2%	$2.5M+5.9%	$2.3M-3.5%	$2.4M
Cost of Revenue	$1.8M+14.5%	$1.6M+12.3%	$1.4M+0.9%	$1.4M-13.1%	$1.6M-6.2%	$1.7M+6.0%	$1.6M-9.9%	$1.8M
Gross Profit	$902K+24.9%	$722K-3.5%	$749K+30.4%	$574K-29.9%	$819K+6.6%	$768K+5.7%	$727K+14.4%	$635K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$757K-7.3%	$817K-7.4%	$882K-0.7%	$888K-3.2%	$917K+6.6%	$860K-2.3%	$881K-13.4%	$1.0M
Operating Income	$145K+253.0%	-$95K+29.1%	-$133K+57.5%	-$314K-219.2%	-$98K-6.7%	-$92K+40.2%	-$154K+59.6%	-$382K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$6K+75.4%	$4K+169.8%	-$5K-208.9%	$5K-13.3%	$6K+394.3%	$1K+103.6%	-$31K-262.9%	$19K
Net Income	$233K+609.0%	$33K+32315.7%	-$102+100.0%	-$204K-314.2%	$95K+1017.1%	$9K-47.0%	$16K+105.2%	-$309K
EPS (Diluted)	$0.01+900.0%	$0.00	N/A	$0.01+125.0%	$0.00	$0.00	N/A	$0.01

PBSV Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$13.5M-15.7%	$16.1M-16.4%	$19.2M-8.0%	$20.9M-5.3%	$22.1M-26.9%	$30.2M
Current Assets	$13.3M-14.2%	$15.5M-17.3%	$18.8M-7.2%	$20.2M-3.7%	$21.0M-27.4%	$28.9M
Cash & Equivalents	$5.8M-21.1%	$7.3M+13.9%	$6.4M-11.2%	$7.2M-52.9%	$15.4M-19.2%	$19.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$2.7M-1.0%	$2.7M+11.4%	$2.4M-44.3%	$4.3M-14.3%	$5.0M-47.2%	$9.6M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.3M-18.9%	$4.1M-19.6%	$5.1M+29.8%	$3.9M-15.8%	$4.6M-47.9%	$8.9M
Current Liabilities	$3.3M-3.2%	$3.4M-7.0%	$3.7M+87.5%	$2.0M-15.5%	$2.3M-58.1%	$5.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$10.2M-14.6%	$12.0M-15.3%	$14.2M-16.7%	$17.0M-2.5%	$17.4M-18.1%	$21.3M
Retained Earnings	$8.8M-16.9%	$10.6M-17.2%	$12.9M-18.1%	$15.7M-3.7%	$16.3M-18.8%	$20.1M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$11.5M-15.1%	$13.5M-0.8%	$13.7M+0.5%	$13.6M-2.3%	$13.9M-13.5%	$16.1M-1.3%	$16.3M-0.2%	$16.3M
Current Assets	$11.3M-15.3%	$13.3M-0.5%	$13.4M+1.8%	$13.2M-2.0%	$13.4M-13.6%	$15.5M-1.0%	$15.7M-1.5%	$15.9M
Cash & Equivalents	$1.8M-68.9%	$5.8M+70.6%	$3.4M-14.6%	$4.0M+89.1%	$2.1M-71.4%	$7.3M+8.0%	$6.8M+3.8%	$6.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$2.7M+2.6%	$2.7M+12.5%	$2.4M+17.1%	$2.0M-24.9%	$2.7M+0.1%	$2.7M+6.8%	$2.5M-3.4%	$2.6M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.0M-68.4%	$3.3M+90.3%	$1.7M+4.8%	$1.7M-6.8%	$1.8M-56.4%	$4.1M+58.4%	$2.6M-2.1%	$2.6M
Current Liabilities	$1.0M-68.4%	$3.3M+90.3%	$1.7M+4.8%	$1.7M-6.8%	$1.8M-48.0%	$3.4M+81.2%	$1.9M-0.6%	$1.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$10.5M+2.1%	$10.2M-14.1%	$11.9M-0.1%	$11.9M-1.6%	$12.1M+1.1%	$12.0M-12.5%	$13.7M+0.2%	$13.7M
Retained Earnings	$9.1M+2.6%	$8.8M-16.0%	$10.5M0.0%	$10.5M-1.9%	$10.7M+0.9%	$10.6M-13.9%	$12.4M+0.1%	$12.3M

PBSV Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$215K+62.1%	-$567K-130.0%	$1.9M+219.2%	$592K-26.4%	$805K-46.9%	$1.5M
Capital Expenditures	$7K-95.8%	$160K+2103.0%	$7K-62.4%	$19K+77.7%	$11K-80.5%	$56K
Free Cash Flow	-$222K+69.5%	-$726K-138.6%	$1.9M+228.6%	$573K-27.8%	$794K-45.6%	$1.5M
Investing Cash Flow	-$1.5M-7.8%	-$1.4M+67.7%	-$4.2M-21791.8%	-$19K-101.5%	$1.3M+4578.1%	-$29K
Financing Cash Flow	-$1.8M-1.0%	-$1.7M+1.4%	-$1.8M+50.2%	-$3.5M-101.3%	-$1.8M-956.5%	$205K
Dividends Paid	$1.7M-0.1%	$1.7M-0.1%	$1.7M-50.0%	$3.4M+99.5%	$1.7M+0.1%	$1.7M
Share Buybacks	$31K+179.2%	$11K-67.2%	$34K-58.1%	$82K+215.8%	$26K+1428.3%	$2K

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$365K+6.4%	-$390K-239.5%	$280K+18.2%	$237K+178.4%	-$302K+29.8%	-$429K-647.6%	$78K+111.7%	-$670K
Capital Expenditures	$2K-3.7%	$2K+588.9%	$350-82.8%	$2K-52.2%	$4K	$0-100.0%	$157K+8129.3%	$2K
Free Cash Flow	-$368K+6.3%	-$393K-240.5%	$279K+19.1%	$234K+176.7%	-$306K+28.8%	-$429K-446.5%	-$79K+88.3%	-$672K
Investing Cash Flow	-$1.9M-168.2%	$2.8M+423.0%	-$857K-152.6%	$1.6M+150.5%	-$3.2M-426.5%	$988K+476.2%	$172K-95.4%	$3.7M
Financing Cash Flow	-$1.7M-102121.1%	-$2K+81.7%	-$9K-83.9%	-$5K+99.7%	-$1.7M	$0	$0+100.0%	-$2K
Dividends Paid	$1.7M	N/A	$0	$0-100.0%	$1.7M	N/A	$0	$0
Share Buybacks	$709-57.8%	$2K-81.7%	$9K+83.9%	$5K-71.0%	$17K	$0	$0-100.0%	$2K

PBSV Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	32.3%+5.9pp	26.5%-3.4pp	29.8%+4.7pp	25.2%-1.5pp	26.7%-4.3pp	30.9%
Operating Margin	-7.1%+6.5pp	-13.5%-20.1pp	6.6%+0.5pp	6.1%+25.2pp	-19.2%-29.5pp	10.3%
Net Margin	-1.1%+7.1pp	-8.2%-15.9pp	7.7%+2.5pp	5.2%+15.6pp	-10.4%-19.9pp	9.5%
Return on Equity	-1.0%+5.5pp	-6.5%-15.7pp	9.3%+3.3pp	5.9%+17.9pp	-12.0%-21.6pp	9.6%
Return on Assets	-0.7%+4.1pp	-4.8%-11.6pp	6.8%+2.0pp	4.8%+14.3pp	-9.5%-16.3pp	6.8%
Current Ratio	4.03-0.5	4.54-0.6	5.10-5.2	10.32+1.3	9.05+3.8	5.23
Debt-to-Equity	0.32-0.0	0.34-0.0	0.36+0.1	0.23-0.0	0.27-0.2	0.42
FCF Margin	-2.5%+5.2pp	-7.6%-18.7pp	11.1%+8.2pp	2.9%-1.0pp	4.0%-2.8pp	6.8%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	33.4%+1.9pp	31.5%-3.4pp	34.8%+5.6pp	29.3%-4.6pp	33.9%+2.8pp	31.1%-0.1pp	31.1%+4.9pp	26.3%
Operating Margin	5.3%+9.5pp	-4.1%+2.1pp	-6.2%+9.8pp	-16.0%-11.9pp	-4.1%-0.3pp	-3.7%+2.9pp	-6.6%+9.2pp	-15.8%
Net Margin	8.6%+7.2pp	1.4%+1.4pp	0.0%+10.4pp	-10.4%-14.3pp	4.0%+3.6pp	0.4%-0.3pp	0.7%+13.5pp	-12.8%
Return on Equity	2.2%+1.9pp	0.3%+0.3pp	-0.0%+1.7pp	-1.7%-2.5pp	0.8%+0.7pp	0.1%-0.0pp	0.1%+2.4pp	-2.3%
Return on Assets	2.0%+1.8pp	0.2%+0.2pp	0.0%+1.5pp	-1.5%-2.2pp	0.7%+0.6pp	0.1%-0.1pp	0.1%+2.0pp	-1.9%
Current Ratio	10.80+6.8	4.03-3.7	7.70-0.2	7.93+0.4	7.54+3.0	4.54-3.8	8.32-0.1	8.39
Debt-to-Equity	0.10-0.2	0.32+0.2	0.150.0	0.140.0	0.15-0.2	0.34+0.2	0.190.0	0.19
FCF Margin	-13.6%+3.5pp	-17.1%-30.1pp	13.0%+1.0pp	11.9%+24.6pp	-12.7%+4.7pp	-17.4%-14.0pp	-3.4%+24.4pp	-27.8%

Similar Companies

UNIDOC HEALTH CORP UDOCF

$6.4M

Vaso Corp VASO

$33.4M

Veri Medtech Holdings VRHI

$40.0M

DiagnaMed Holdings Corp DGNMF

$4.5M

Retrieve Medical Holdings Inc RMHI

$28.0M

Frequently Asked Questions

What is Pharma-Bio Serv Inc's annual revenue?

Pharma-Bio Serv Inc (PBSV) reported $9.0M in total revenue for fiscal year 2025. This represents a -5.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Pharma-Bio Serv Inc's revenue growing?

Pharma-Bio Serv Inc (PBSV) revenue declined by 5.3% year-over-year, from $9.5M to $9.0M in fiscal year 2025.

Is Pharma-Bio Serv Inc profitable?

No, Pharma-Bio Serv Inc (PBSV) reported a net income of -$100K in fiscal year 2025, with a net profit margin of -1.1%.

What is Pharma-Bio Serv Inc's EBITDA?

Pharma-Bio Serv Inc (PBSV) had EBITDA of -$578K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Pharma-Bio Serv Inc's gross margin?

Pharma-Bio Serv Inc (PBSV) had a gross margin of 32.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Pharma-Bio Serv Inc's operating margin?

Pharma-Bio Serv Inc (PBSV) had an operating margin of -7.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Pharma-Bio Serv Inc's net profit margin?

Pharma-Bio Serv Inc (PBSV) had a net profit margin of -1.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Pharma-Bio Serv Inc's return on equity (ROE)?

Pharma-Bio Serv Inc (PBSV) has a return on equity of -1.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Pharma-Bio Serv Inc's free cash flow?

Pharma-Bio Serv Inc (PBSV) generated -$222K in free cash flow during fiscal year 2025. This represents a 69.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Pharma-Bio Serv Inc's operating cash flow?

Pharma-Bio Serv Inc (PBSV) generated -$215K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Pharma-Bio Serv Inc's total assets?

Pharma-Bio Serv Inc (PBSV) had $13.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Pharma-Bio Serv Inc's capital expenditures?

Pharma-Bio Serv Inc (PBSV) invested $7K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does Pharma-Bio Serv Inc buy back shares?

Yes, Pharma-Bio Serv Inc (PBSV) spent $31K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Pharma-Bio Serv Inc have outstanding?

Pharma-Bio Serv Inc (PBSV) had 23M shares outstanding as of fiscal year 2025.

What is Pharma-Bio Serv Inc's current ratio?

Pharma-Bio Serv Inc (PBSV) had a current ratio of 4.03 as of fiscal year 2025, which is generally considered healthy.

What is Pharma-Bio Serv Inc's debt-to-equity ratio?

Pharma-Bio Serv Inc (PBSV) had a debt-to-equity ratio of 0.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Pharma-Bio Serv Inc's return on assets (ROA)?

Pharma-Bio Serv Inc (PBSV) had a return on assets of -0.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Pharma-Bio Serv Inc's cash runway?

Based on fiscal year 2025 data, Pharma-Bio Serv Inc (PBSV) had $5.8M in cash against an annual operating cash burn of $215K. This gives an estimated cash runway of approximately 322 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Pharma-Bio Serv Inc's Altman Z-Score?

Pharma-Bio Serv Inc (PBSV) has an Altman Z-Score of 4.05, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Pharma-Bio Serv Inc's Piotroski F-Score?

Pharma-Bio Serv Inc (PBSV) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Pharma-Bio Serv Inc's earnings high quality?

Pharma-Bio Serv Inc (PBSV) has an earnings quality ratio of 2.14x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.